Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study.

被引：0
|
作者：
Means-Powell, Julie Ann
Adjei, Alex A.
Puzanov, Igor
Dy, Grace K.
Goff, Laura Williams
Ma, Wen Wee
Fetterly, Gerald J.
Michael, Shaunita A.
Chai, Feng
Lamar, Maria
Schwartz, Brian E.
Sosman, Jeffrey Alan
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[3] ArQule Inc, Woburn, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8519
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors
    Mekhail, T.
    Rich, T.
    Rosen, L.
    Chai, F.
    Semic-Suka, Z.
    Savage, R. E.
    Senzer, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Phase I pharmacokinetic study of an oral, small-molecule MEK inhibitor tunlametinib in patients with advanced NRAS mutant melanoma
    Zhao, Qian
    Wang, Teng
    Wang, Huanhuan
    Cui, Cheng
    Zhong, Wen
    Fu, Diyi
    Xi, Wanlin
    Si, Lu
    Guo, Jun
    Cheng, Ying
    Tian, Hongqi
    Hu, Pei
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [23] Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-Met inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy
    Eng, C.
    Bendell, J. C.
    Bessudo, A.
    Gabrail, N. Y.
    Diamond, J.
    Pande, A. U.
    Gorbatchevsky, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [24] Phase I results of the randomized, placebo controlled, phase I/II study of the novel oral c-MET inhibitor, ARQ 197, irinotecan (CPT-11), and cetuximab (C) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC) who have received front-line systemic therapy
    Bessudo, A.
    Bendell, J. C.
    Gabrail, N.
    Kopp, M. V.
    Mueller, L.
    Hart, L. L.
    Vladimirov, V. I.
    Pande, A. U.
    Gorbatchevsky, I.
    Eng, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Immune checkpoint-Inhibition in Patients with NRAS-mutated Melanoma compared to Patients with NRAS Wild-type Melanoma - Results of a Study on 702 Patients from the prospective, multicenter Registry ADOREG
    Zaremba, A.
    Griewank, K.
    Mohr, P.
    Gutzmer, R.
    Pfoehler, C.
    Meier, F.
    Weichenthal, M.
    Terheyden, P.
    Forschner, A.
    Leiter-Stoeppke, U.
    Ulrich, J.
    Kaatz, M.
    Welzel, J.
    Utikal, J. S.
    Livingstone, E.
    Schadendorf, D.
    Ugurel, S.
    Zimmer, L.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 59 - 60
  • [26] Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma
    Dummer, Reinhard
    Michielin, Olivier
    Nageli, Mirjam Chantal
    Goldinger, Simone M.
    Campigotto, Federico
    Kriemler-Krahn, Ulrike
    Schmid, Herbert
    Pedroncelli, Alberto
    Micaletto, Sara
    Schadendorf, Dirk
    ESMO OPEN, 2018, 3 (05)
  • [27] A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy
    Eng, Cathy
    Bessudo, Alberto
    Hart, Lowell L.
    Severtsev, Aleksey
    Gladkov, Oleg
    Mueller, Lothar
    Kopp, Mikhail V.
    Vladimirov, Vladimir
    Langdon, Robert
    Kotiv, Bogdan
    Barni, Sandro
    Hsu, Ching
    Bolotin, Ellen
    von Roemeling, Reinhard
    Schwartz, Brian
    Bendell, Johanna C.
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (01) : 177 - 186
  • [28] A phase I, open-label study of pasireotide in patients with BRAF-and NRAS-wild type, unresectable and or metastatic melanoma
    Dummer, R.
    Michielin, O. A.
    Nageli, M.
    Goldinger, S. M.
    Campigotto, F.
    Kriemler-Krahn, U.
    Schmid, H.
    Pedroncelli, A.
    Micaletto, S.
    Schadendorf, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] APOLLON: A phase I/II study of panitumumab combined with TAS-102 in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC).
    Kuboki, Yasutoshi
    Yoshino, Takayuki
    Kato, Takeshi
    Kagawa, Yoshinori
    Gamoh, Makio
    Yasui, Hirofumi
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Satake, Hironaga
    Goto, Masahiro
    Tanioka, Hiroaki
    Oki, Eiji
    Kotaka, Masahito
    Makiyama, Akitaka
    Denda, Tadamichi
    Soeda, Junpei
    Shibuya, Kazunori
    Iwata, Masaru
    Oba, Koji
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Efficacy and safety of first-line cetuximab plus FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study.
    Van Cutsem, Eric
    Kohne, Claus-Henning
    Folprecht, Gunnar
    Guenther, Silke
    Beier, Frank
    Papamichael, Demetris
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345